Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D L Trump

Showing results (101-110 of 145) with videos related to

Pageof 15
Sort By:
Urology|October 1, 1985
Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer GroupW W Koontz, N M Heney, M S Soloway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer riskF Modugno, J L Weissfeld, D L Trump, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trialW P Petros, S G Chaney, D C Smith, et al.
The Journal of Urology|November 1, 1990
Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology GroupD L Trump, P Elson, S Madajewicz, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysisD L Trump, D C Smith, D Stiff, et al.
Cancer Chemotherapy and Pharmacology|November 7, 1999
A phase II trial of CI-958 in patients with hormone-refractory prostate cancerP V Woolley, F S Freiha, D C Smith, et al.
Investigational New Drugs|January 1, 1990
A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot studyD L Trump, J C Marsh, L K Kvols, et al.
Investigational New Drugs|February 1, 1991
A phase II study of taxol in patients with malignant melanomaA I Einzig, H Hochster, P H Wiernik, et al.
American Journal of Clinical Oncology|October 1, 1990
Phase II trial of carboplatin in soft-tissue sarcomaD Goldstein, B Cheuvart, D L Trump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1987
Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancerF R Ahmann, D L Citrin, H A deHaan, et al.
Pageof 15

Showing results (101-110 of 145) with videos related to

Sort By:
Pageof 15
Urology|October 1, 1985
Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer GroupW W Koontz, N M Heney, M S Soloway, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer riskF Modugno, J L Weissfeld, D L Trump, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trialW P Petros, S G Chaney, D C Smith, et al.
The Journal of Urology|November 1, 1990
Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology GroupD L Trump, P Elson, S Madajewicz, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysisD L Trump, D C Smith, D Stiff, et al.
Cancer Chemotherapy and Pharmacology|November 7, 1999
A phase II trial of CI-958 in patients with hormone-refractory prostate cancerP V Woolley, F S Freiha, D C Smith, et al.
Investigational New Drugs|January 1, 1990
A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot studyD L Trump, J C Marsh, L K Kvols, et al.
Investigational New Drugs|February 1, 1991
A phase II study of taxol in patients with malignant melanomaA I Einzig, H Hochster, P H Wiernik, et al.
American Journal of Clinical Oncology|October 1, 1990
Phase II trial of carboplatin in soft-tissue sarcomaD Goldstein, B Cheuvart, D L Trump, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1987
Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancerF R Ahmann, D L Citrin, H A deHaan, et al.
Pageof 15